A new analysis by researchers at the University of Pennsylvania School of Medicine of recent cardiology clinical practice guidelines has found that more than half of the experts involved in the development of these guidelines reported a conflict of interest (COI).
“The extent of COIs in cardiology guideline production had not been well studied up to this point. Our findings that most episodes of guidelines participation involve COIs, and that most individuals involved in producing guidelines report COIs, is a cause for concern,” said corresponding author James N. Kirkpatrick, MD, assistant professor of Medicine and colleagues at Penn. “However, the results of this study also highlight that a strong pool of experts without any COIs are available to direct the clinical practice guideline development process.”
For the analysis, the researchers examined 17 different cardiology guidelines through 2008. Using disclosure lists from the actual guidelines, the researchers cataloged COIs for each participant as receiving a research grant, being on a speaker's bureau and/or receiving honoraria, owning stock, or being a consultant or member of an advisory board. The researchers also cataloged the companies and institutions reported in each disclosure. "Episode" describes one instance of participation in one guideline by one person. "Individual" describes one person who may be involved in multiple episodes.
In the 17 guidelines, the researchers found 651 episodes of participation by 498 individuals. A total of 277 of the 498 individuals (56 percent) reported a COI. On average, each individual participated in 1.31 episodes. Over half of the episodes (365 of 651 [56 percent]) involved a COI. The most common form of COI was consultant/advisory board, followed by research grant, honoraria/speakers' bureau, and stock/other ownership.
The analysis results are reported in the March 28 issue of
Archives of Internal Medicine. For more information, please see the
Archives of Internal Medicine press release:
http://pubs.ama-assn.org/homepage/media/2011a/0328.dtl#3
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.